News
ATXI
0.300
0.00%
0.000
Weekly Report: what happened at ATXI last week (0504-0508)?
Weekly Report · 6d ago
Avenue Therapeutics Q1 EPS $(0.21) Up From $(0.62) YoY
Benzinga · 05/08 13:53
Weekly Report: what happened at ATXI last week (0427-0501)?
Weekly Report · 05/04 09:57
Weekly Report: what happened at ATXI last week (0420-0424)?
Weekly Report · 04/27 09:58
Weekly Report: what happened at ATXI last week (0413-0417)?
Weekly Report · 04/20 09:55
Weekly Report: what happened at ATXI last week (0406-0410)?
Weekly Report · 04/13 09:58
Weekly Report: what happened at ATXI last week (0330-0403)?
Weekly Report · 04/06 09:58
Weekly Report: what happened at ATXI last week (0323-0327)?
Weekly Report · 03/30 09:59
Weekly Report: what happened at ATXI last week (0316-0320)?
Weekly Report · 03/23 09:55
Weekly Report: what happened at ATXI last week (0309-0313)?
Weekly Report · 03/16 09:55
Weekly Report: what happened at ATXI last week (0302-0306)?
Weekly Report · 03/09 09:56
Weekly Report: what happened at ATXI last week (0223-0227)?
Weekly Report · 03/02 09:55
Avenue Therapeutics enters worldwide license agreement for ATX-04
TipRanks · 02/23 13:21
Weekly Report: what happened at ATXI last week (0216-0220)?
Weekly Report · 02/23 09:55
Weekly Report: what happened at ATXI last week (0209-0213)?
Weekly Report · 02/16 09:55
Weekly Report: what happened at ATXI last week (0202-0206)?
Weekly Report · 02/09 09:56
Weekly Report: what happened at ATXI last week (0126-0130)?
Weekly Report · 02/02 09:56
Weekly Report: what happened at ATXI last week (0119-0123)?
Weekly Report · 01/26 09:56
Weekly Report: what happened at ATXI last week (0112-0116)?
Weekly Report · 01/19 10:00
Weekly Report: what happened at ATXI last week (0105-0109)?
Weekly Report · 01/12 09:59
More
Webull provides a variety of real-time ATXI stock news. You can receive the latest news about Avenue Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATXI
Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patient’s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.